Application of PROTACs in antiviral drugs
10.11665/j.issn.1000-5048.2025100701
- VernacularTitle:PROTACs在抗病毒药物研发中的应用
- Author:
Miaoxia PU
1
;
Shuangshuang ZHANG
;
Haifeng WANG
;
Yuanyuan ZHU
;
Shuangxi GU
Author Information
1. 武汉工程大学 化工与制药学院 药物研究院, 武汉430205;武汉工程大学 化学与环境工程学院, 武汉430205
- Publication Type:Journal Article
- Keywords:
proteolysis-targeting chimeras (PROTACs);
ubiquitin-proteasome system;
antiviral drugs;
target protein degradation;
drug resistance
- From:
Journal of China Pharmaceutical University
2025;56(6):667-677
- CountryChina
- Language:Chinese
-
Abstract:
Proteolysis-targeting chimeras (PROTACs) have shown considerable therapeutic potential across diverse fields such as cancer, inflammation, and neurodegenerative diseases, with numerous candidates already progressing into clinical trials. More recently, their application in antiviral therapy has been rapidly gaining momentum. This review systematically outlines the mechanistic foundations and design principles of PROTACs, highlights recent advances targeting coronaviruses (including SARS-CoV-2), hepatitis C virus, human immunodeficiency virus, and influenza viruses, and critically assesses key challenges—particularly the limited diversity of E3 ligase ligands, suboptimal oral bioavailability, and the lack of integrated platforms for druggability evaluation. Looking ahead, innovations in ligand discovery, pathway modulation, delivery technologies, and conditionally activated PROTAC designs are anticipated to overcome these barriers, ushering in a new era of precise and effective antiviral therapeutics.
